Omission of sentinel lymph node biopsy in early stage luminal breast cancer: impact on adjuvant CDK4/6 inhibitor recommendation and oncological outcomes
Omission of SLNB in patients with small HR-positive/HER2-negative tumors results in a missed indication for CDK4/6i in <8 % with minimal impact on recurrence.
Authors
- Fabienne Dominique Schwab (ORCID: https://orcid.org/0000-0003-1124-3780)
- Nadia Maggi (ORCID: https://orcid.org/0000-0002-9483-0245)
- Giacomo Montagna (ORCID: https://orcid.org/0000-0003-3511-369X)
- Florian Samuel Halbeisen (ORCID: https://orcid.org/0000-0003-2755-9501)
- Marie Louise Frevert (ORCID: https://orcid.org/0000-0002-6497-7051)
- Martin Heidinger
- Tibor A. Zwimpfer (ORCID: https://orcid.org/0000-0002-1574-6572)
- William P. Weber (ORCID: https://orcid.org/0000-0003-1667-7844)
- Rama Kiblawi (ORCID: https://orcid.org/0000-0002-6887-5730)
- Christian Kurzeder (ORCID: https://orcid.org/0000-0003-4368-7490)
- Julie M Loesch
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Basel (CH)
- University Hospital of Basel (CH)
- Hospital Base (CL)
Publication Details
- Journal
- The Breast
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1016/j.breast.2025.104641
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52